About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biotech developing VK2735, a GLP-1/GIP dual agonist for obesity, in Phase 3 trials. High beta, no dividend, sentiment-driven swings tied to trial data and obesity-drug competition. Rich premiums but extreme gap risk around data readouts makes CSP selling high-risk.
Biotechnology